Hedging Longevity Risk in Life Settlements Using Biomedical Research-Backed Obligations

Richard D. MacMinn, Nan Zhu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the life settlement market, mortality risk is transferred from life insurance policyholders to third-party life settlement firms. This risk transfer occurs in conjunction with an information transfer that is relevant not only for pricing, but also for risk management. In this analysis, we compare the efficiency of two different hedging instruments in managing the mortality risk of the life settlement firm. First, we claim and then demonstrate that conventional longevity-linked securities do not perform as effectively in the secondary life market, that is, life settlement market, as in the annuity and pension markets due to the basis risk that exists between the general population and the life settlement subgroup. Second, we show that the unique risk exposure of the life settlement firm can be specifically targeted using a new instrument—the biomedical research-backed obligations. Our finding connects two seemingly independent markets and can promote the healthy development of both.

Original languageEnglish (US)
Pages (from-to)439-458
Number of pages20
JournalJournal of Risk and Insurance
Volume84
DOIs
StatePublished - Apr 1 2017

Fingerprint

Biomedical research
Obligation
Longevity risk
Hedging
Mortality risk
Risk exposure
Pricing
Risk transfer
General population
Risk management
Information transfer
Annuities
Life insurance
Basis risk
Pensions

All Science Journal Classification (ASJC) codes

  • Accounting
  • Finance
  • Economics and Econometrics

Cite this

@article{7163ad41e1f04c71ab9f416c08c7342c,
title = "Hedging Longevity Risk in Life Settlements Using Biomedical Research-Backed Obligations",
abstract = "In the life settlement market, mortality risk is transferred from life insurance policyholders to third-party life settlement firms. This risk transfer occurs in conjunction with an information transfer that is relevant not only for pricing, but also for risk management. In this analysis, we compare the efficiency of two different hedging instruments in managing the mortality risk of the life settlement firm. First, we claim and then demonstrate that conventional longevity-linked securities do not perform as effectively in the secondary life market, that is, life settlement market, as in the annuity and pension markets due to the basis risk that exists between the general population and the life settlement subgroup. Second, we show that the unique risk exposure of the life settlement firm can be specifically targeted using a new instrument—the biomedical research-backed obligations. Our finding connects two seemingly independent markets and can promote the healthy development of both.",
author = "MacMinn, {Richard D.} and Nan Zhu",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/jori.12200",
language = "English (US)",
volume = "84",
pages = "439--458",
journal = "Journal of Risk and Insurance",
issn = "0022-4367",
publisher = "Wiley-Blackwell",

}

Hedging Longevity Risk in Life Settlements Using Biomedical Research-Backed Obligations. / MacMinn, Richard D.; Zhu, Nan.

In: Journal of Risk and Insurance, Vol. 84, 01.04.2017, p. 439-458.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hedging Longevity Risk in Life Settlements Using Biomedical Research-Backed Obligations

AU - MacMinn, Richard D.

AU - Zhu, Nan

PY - 2017/4/1

Y1 - 2017/4/1

N2 - In the life settlement market, mortality risk is transferred from life insurance policyholders to third-party life settlement firms. This risk transfer occurs in conjunction with an information transfer that is relevant not only for pricing, but also for risk management. In this analysis, we compare the efficiency of two different hedging instruments in managing the mortality risk of the life settlement firm. First, we claim and then demonstrate that conventional longevity-linked securities do not perform as effectively in the secondary life market, that is, life settlement market, as in the annuity and pension markets due to the basis risk that exists between the general population and the life settlement subgroup. Second, we show that the unique risk exposure of the life settlement firm can be specifically targeted using a new instrument—the biomedical research-backed obligations. Our finding connects two seemingly independent markets and can promote the healthy development of both.

AB - In the life settlement market, mortality risk is transferred from life insurance policyholders to third-party life settlement firms. This risk transfer occurs in conjunction with an information transfer that is relevant not only for pricing, but also for risk management. In this analysis, we compare the efficiency of two different hedging instruments in managing the mortality risk of the life settlement firm. First, we claim and then demonstrate that conventional longevity-linked securities do not perform as effectively in the secondary life market, that is, life settlement market, as in the annuity and pension markets due to the basis risk that exists between the general population and the life settlement subgroup. Second, we show that the unique risk exposure of the life settlement firm can be specifically targeted using a new instrument—the biomedical research-backed obligations. Our finding connects two seemingly independent markets and can promote the healthy development of both.

UR - http://www.scopus.com/inward/record.url?scp=85011665586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011665586&partnerID=8YFLogxK

U2 - 10.1111/jori.12200

DO - 10.1111/jori.12200

M3 - Article

AN - SCOPUS:85011665586

VL - 84

SP - 439

EP - 458

JO - Journal of Risk and Insurance

JF - Journal of Risk and Insurance

SN - 0022-4367

ER -